
Opinion|Videos|April 8, 2024
Safety Profile of GVHD Treatment Options
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Episodes in this series

















